PURPOSE: Differences in tumor biology, genomic architecture, and health care delivery patterns contribute to the breast cancer mortality gap between White and Black patients in the US. Although this gap has been well documented in previous literature, it remains uncertain how large the actual effect size of race is for different survival outcomes and the four breast cancer subtypes. METHODS: We established a breast cancer patient cohort at the University of Chicago Comprehensive Cancer Center. We chose five major survival outcomes to study: overall survival, recurrence-free survival, breast-cancer-specific survival, time-to-recurrence and post-recurrence survival. Cox proportional hazards models were used to estimate the hazard ratios between Black and White patients, adjusting for selected patient, tumor, and treatment characteristics, and also stratified by the four breast cancer subtypes. RESULTS: The study included 2795 stage I-III breast cancer patients (54% White and 38% Black). After adjusting for selected patient, tumor and treatment characteristics, Black patients still did worse than White patients in all five survival outcomes. The racial difference was highest within the HR-/HER2+ subgroup, in both overall survival (hazard ratio = 4.00, 95% CI 1.47-10.86) and recurrence-free survival (hazard ratio = 3.00, 95% CI 1.36-6.60), adjusting for age at diagnosis, cancer stage, and comorbidities. There was also a significant racial disparity within the HR+/HER2- group in both overall survival and recurrence-free survival. CONCLUSIONS: Our study confirmed that racial disparity existed between White and Black breast cancer patients in terms of both survival and recurrence, and found that this disparity was largest among HR-/HER2+ and HR+/HER2- patients.
PURPOSE: Differences in tumor biology, genomic architecture, and health care delivery patterns contribute to the breast cancer mortality gap between White and Black patients in the US. Although this gap has been well documented in previous literature, it remains uncertain how large the actual effect size of race is for different survival outcomes and the four breast cancer subtypes. METHODS: We established a breast cancer patient cohort at the University of Chicago Comprehensive Cancer Center. We chose five major survival outcomes to study: overall survival, recurrence-free survival, breast-cancer-specific survival, time-to-recurrence and post-recurrence survival. Cox proportional hazards models were used to estimate the hazard ratios between Black and White patients, adjusting for selected patient, tumor, and treatment characteristics, and also stratified by the four breast cancer subtypes. RESULTS: The study included 2795 stage I-III breast cancer patients (54% White and 38% Black). After adjusting for selected patient, tumor and treatment characteristics, Black patients still did worse than White patients in all five survival outcomes. The racial difference was highest within the HR-/HER2+ subgroup, in both overall survival (hazard ratio = 4.00, 95% CI 1.47-10.86) and recurrence-free survival (hazard ratio = 3.00, 95% CI 1.36-6.60), adjusting for age at diagnosis, cancer stage, and comorbidities. There was also a significant racial disparity within the HR+/HER2- group in both overall survival and recurrence-free survival. CONCLUSIONS: Our study confirmed that racial disparity existed between White and Black breast cancer patients in terms of both survival and recurrence, and found that this disparity was largest among HR-/HER2+ and HR+/HER2- patients.
Entities:
Keywords:
Breast cancer; Racial disparity; Recurrence; Subtype; Survival
Authors: William J Gradishar; Benjamin O Anderson; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Lori J Goldstein; Daniel F Hayes; Clifford A Hudis; Steven J Isakoff; Britt-Marie E Ljung; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Robert S Miller; Mark Pegram; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Mary Lou Smith; Hatem Soliman; George Somlo; John H Ward; Antonio C Wolff; Richard Zellars; Dorothy A Shead; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2014-04 Impact factor: 11.908
Authors: Katie M O'Brien; Stephen R Cole; Chiu-Kit Tse; Charles M Perou; Lisa A Carey; William D Foulkes; Lynn G Dressler; Joseph Geradts; Robert C Millikan Journal: Clin Cancer Res Date: 2010-12-15 Impact factor: 12.531
Authors: A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood Journal: Lancet Date: 1984-03-17 Impact factor: 79.321
Authors: M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Soo Youn Bae; Sangmin Kim; Jun Ho Lee; Hyun-Chul Lee; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam Journal: BMC Cancer Date: 2015-03-18 Impact factor: 4.430
Authors: Kara Keun Lee; Lavanya Rishishwar; Dongjo Ban; Shashwat Deepali Nagar; Leonardo Mariño-Ramírez; John F McDonald; I King Jordan Journal: Cancer Res Date: 2022-04-01 Impact factor: 13.312
Authors: Fangyuan Zhao; Tara O Henderson; Toni M Cipriano; Brenda L Copley; Michelle Liu; Rahul Burra; Sondra H Birch; Olufunmilayo I Olopade; Dezheng Huo Journal: Cancer Date: 2021-07-22 Impact factor: 6.921